Key result
High cardiometabolic index linked to ~50% higher odds of WHO-defined high CVD risk.
Why the study?
The cardiometabolic index, reflecting central adiposity and dyslipidemia, may offer a pragmatic tool for community cardiovascular risk screening.
Is the cardiometabolic index associated with WHO-defined high cardiovascular disease risk in a community screening cohort?
Cross-Sectional (n=6,701)
No
Is the cardiometabolic index associated with WHO-defined high cardiovascular disease risk in a community screening cohort?
Higher cardiometabolic index is nonlinearly associated with WHO-defined high cardiovascular risk, supporting its potential as an adjunct screening marker.
Background The cardiometabolic index (CMI), a composite marker reflecting central adiposity and dyslipidemia, may offer a pragmatic tool for community cardiovascular risk screening. Methods We analyzed cross-sectional screening data from the ChinaHEART Luohe cohort. WHO chart-defined CVD high risk was a 10-year predicted risk ≥20%. CMI was evaluated per 1-unit increase and, for descriptive and stratified analyses, dichotomized using a rounded pragmatic analytic threshold of 0.7 derived from a crude ROC/Youden optimal threshold of 0.723. Discrimination (AUC with bootstrap 95% CIs), raincloud plots, restricted cubic splines (RCS), stepwise logistic regression, subgroup/interaction analyses, and an explainable ML pipeline (LASSO-random forest-SHAP) were applied. Results Among 6,701 participants, 1,439 (21%) were classified as CVD high risk; prevalence was higher in the high-CMI group (≥0.7) than the low-CMI group (29% vs. 18%). CMI alone showed modest discrimination for WHO-defined CVD high-risk status (AUC: 0.571, 95% CI: 0.555–0.586), whereas multivariable models incorporating CMI showed higher discrimination (Model 3 AUC: 0.642, 95% CI: 0.626–0.659). The raincloud plot showed higher CMI in the high-risk group ( P < 0.001), and RCS suggested nonlinearity ( P for overall < 0.001; P for nonlinearity = 0.020). In Model 3, CMI was associated with higher odds of CVD high risk (OR: 1.31, 95% CI: 1.16–1.48 per 1-unit; OR: 1.50, 95% CI: 1.32–1.71 for ≥0.7 vs. <0.7). In ML, random forest achieved AUC 0.814; SHAP ranked CMI 3rd of 7 LASSO-selected features. Conclusions Higher CMI was associated with WHO-defined CVD high-risk status with a nonlinear pattern and consistent importance across conventional and explainable ML analyses, supporting its potential utility as an adjunct screening marker.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cross-sectional in Cardiovascular disease high risk (n=6,701). High cardiometabolic index (CMI ≥ 0.7) vs. Low cardiometabolic index (CMI < 0.7) was evaluated on WHO chart-defined CVD high-risk status (10-year predicted risk ≥ 20%) (OR 1.50, 95% CI 1.32-1.71, p=<0.001). High cardiometabolic index (≥0.7) was associated with 50% higher odds of WHO-defined cardiovascular disease high-risk status compared to low index (<0.7) (OR 1.50).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: